The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings per share were $0.62, exceeding guidance of at least $0.60 at constant exchange rates. Product-group performance variedSample Technologies sales increased 9% at constant exchange rates, supported by automated consumables and higher instrument sales compared with the prior-year period. Diagnostic Solutions revenue declined 2% at constant exchange rates. QIAstat-Dx sales fell 7% at constant exchange rates.